Cargando…

Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer

BACKGROUND: SCOT was an international, randomized phase 3 trial of 3 months vs 6 months of adjuvant chemotherapy with oxaliplatin and a fluoropyrimidine in patients with colorectal cancer. We sought patients’ preferences for 3 months vs 6 months of adjuvant chemotherapy in the SCOT trial. METHODS: S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blinman, Prunella, Martin, Andrew, Jefford, Michael, Goldstein, David, Boadle, David, Morris, Michelle, Tebbutt, Niall, Aiken, Christine, Harkin, Andrea, Segelov, Eva, Haydon, Andrew, Iveson, Tim, Stockler, Martin R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883552/ https://www.ncbi.nlm.nih.gov/pubmed/34159294 http://dx.doi.org/10.1093/jncics/pkaa107

Ejemplares similares

What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in the SORCE Trial
por: Lawrence, Nicola J., et al.
Publicado: (2018)

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial
por: Blinman, Prunella, et al.
Publicado: (2016)

Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study
por: Blinman, Prunella, et al.
Publicado: (2013)

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
por: Iveson, Timothy J, et al.
Publicado: (2018)

Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer
por: Iveson, Timothy J., et al.
Publicado: (2021)

Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial
por: Teng, Christina, et al.
Publicado: (2022)

Scanxiety Conversations on Twitter: Observational Study
por: Bui, Kim Tam, et al.
Publicado: (2023)

Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma—A Discrete Choice Experiment
por: Livingstone, Ann, et al.
Publicado: (2023)

Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?
por: Boyd, Kathleen A, et al.
Publicado: (2011)

Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature
por: Chan, David L., et al.
Publicado: (2015)

Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature
por: Chan, David L., et al.
Publicado: (2015)

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
por: Segelov, Eva, et al.
Publicado: (2016)

Scanxiety: a scoping review about scan-associated anxiety
por: Bui, Kim Tam, et al.
Publicado: (2021)

Effect of 6-month vs. 8-month regimen on retreatment success for pulmonary TB
por: Izudi, J., et al.
Publicado: (2022)

Six Months vs. 12 Months of Adjuvant Trastuzumab Among Women With HER2-Positive Early-Stage Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Deng, Huan, et al.
Publicado: (2020)

How long is too long? A scoping review of health system delays in lung cancer
por: Malalasekera, Ashanya, et al.
Publicado: (2018)

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
por: Saini, A, et al.
Publicado: (2003)

Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?
por: Duric, V M, et al.
Publicado: (2005)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
por: Mathews, Maju, et al.
Publicado: (2018)

Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07
por: Kim, Seung Tae, et al.
Publicado: (2022)

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016)

An update on adjuvant systemic therapies in melanoma
por: Samuel, Evangeline, et al.
Publicado: (2019)

UX15-month-by-month
Publicado: (2003)

UX15-month-by-month
Publicado: (2004)

The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours
por: Foo, Tiffany, et al.
Publicado: (2022)

Physical activity habits and preferences in the month prior to a first-ever stroke
por: McDonnell, Michelle N., et al.
Publicado: (2014)

Social encouragement can influence manual preference in 6 month-old-infants
por: Morange-Majoux, Françoise, et al.
Publicado: (2014)

Preference for Telehealth Sustained Over Three Months at an Outpatient Center for Integrative Medicine
por: Finn, Michael T. M., et al.
Publicado: (2021)

Three Months-Old’ Preferences for Biological Motion Configuration and Its Subsequent Decline
por: Lisboa, Isabel C., et al.
Publicado: (2022)

SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
por: Robles-Zurita, José, et al.
Publicado: (2018)

Superior virologic and treatment outcomes when viral load is measured at 3 months compared to 6 months on antiretroviral therapy
por: Kerschberger, Bernhard, et al.
Publicado: (2015)

Adrenocortical Carcinoma in an Adult: Eight Months without Recurrence after Resection and Adjuvant Chemotherapy
por: Siosaki, Marcos Duarte, et al.
Publicado: (2014)

Revealed distributional preferences: Individuals vs. teams()()
por: Balafoutas, Loukas, et al.
Publicado: (2014)

Acceptability and Preference for 3-Month Versus 1-Month Vaginal Rings for HIV-1 Risk Reduction Among Participants in a Phase 1 Trial
por: Roberts, Sarah T., et al.
Publicado: (2022)

The Month
Publicado: (1857)

The Month
Publicado: (1857)

The Month
Publicado: (1857)

The Month
Publicado: (1857)

The Month
Publicado: (1857)

The Month
Publicado: (1857)

Cannot write session to /tmp/vufind_sessions/sess_76ifjm6on8caathir7s2mit418